A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: Insight to the drug release mechanisms

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 217-222

  Kamberi, Marika ^a   Nayak, Sushma ^a   Myo Min, Kathy ^a   Carter, Troy P ^a   Hancock, Leonard ^a   Feder, Debra ^a  

^a ABBOTT VASCULAR   (United States)

Author keywords

Drug eluting stent; Everolimus; HPLC GPC; In vitro release kinetics; PLGA; Release medium; SEM

Indexed keywords

ACETONITRILE; EVEROLIMUS; POLYSORBATE 20;

ARTICLE; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG COATING; DRUG DEGRADATION; DRUG DETERMINATION; DRUG DIFFUSION; DRUG ELUTING STENT; DRUG MANUFACTURE; DRUG SOLUBILITY; GEL PERMEATION CHROMATOGRAPHY; IMMERSION; IN VITRO STUDY; MOLECULAR WEIGHT; POROSITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; QUALITY CONTROL; SCANNING ELECTRON MICROSCOPE; SURFACE PROPERTY;

ABSORBABLE IMPLANTS; CHROMATOGRAPHY, GEL; DRUG-ELUTING STENTS; ELECTRONS; EXCIPIENTS; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; POLYGLYCOLIC ACID; SIROLIMUS; SOLUBILITY; SOLVENTS;

EID: 67349244031     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.02.009     Document Type: Article

References (53)

1. Acharya G., and Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv. Drug Deliv. Rev. 58 (2006) 387-401
2. Agrawal C.M., Huang D., Schmitz J.P., and Athanasiou K.A. Elevated temperature degradation of a 50:50 copolymer of PLA-PGA. Tissue Eng. 3 (1997) 345-352
3. Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly((lactic acid)-co-(glycolic acid)). Polym. Int. 54 (2005) 36-46
4. Altman R., and Scazziota A. Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From athero-inflammation to athero-thrombosis. Rev. Esp. Cardiol. 56 (2003) 9-15
5. Aso Y., Yoshioka S., Li-Wan-Po A., and Terao T. Effect of molecular weight and storage times on tolmetin release from poly-d,l-lactide microspheres to lipid model membrane. A calorimetric study. J. Control. Release 31 (1994) 33-39
6. Beijk M.A., and Piek J.J. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert. Rev. Med. Dev. 4 (2007) 11-21
7. Biondi-Zoccai G., Lotrionte M., Moretti C., Agostoni P., Sillano D., Laudito A., and Sheiban I. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher). Miner. Cardioangiol. 56 (2008) 55-65
8. Burgess D.J., Hussain A.S., Ingallinera T.S., and Chen A.-L. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS Pharm. Sci. 4 (2002) E7
9. Chapman T.M., and Perry C.M. Everolimus. Drugs 64 (2004) 861-872
10. Chiu L.K., Chiu W.J., and Cheng Y.-L. Effects of polymer degradation on drug released-mechanistic study of morphology and transport properties in 50:50 poly(d,l-lactide-co-glycolide). Int. J. Pharm. 126 (1995) 169-178
11. Cort T.L., Song M.-S., and Bielefeldt A.R. Nonionic surfactant effects on pentachlorophenol biodegradation. Water Res. 36 (2002) 1253-1261
12. Cristescu R., Cojanu C., Popescu A., Grigorescu S., Nastase C., Nastase F., Doraiswamy A., Narayan R.J., Stamatin I., Mihailescu I.N., and Chrisey D.B. Processing of poly (1,3-bis-(p-carboxyphenoxy propane)-co-(sebacic anhydride)) 20:80 (P(CPP:SA)20:80) by matrix-assisted pulsed laser evaporation for drug delivery systems. Appl. Surf. Sci. 254 (2007) 1169-1173
13. Faisant N., Akiki J., Siepmann F., Benoit J.P., and Siepmann J. Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory. Int. J. Pharm. 314 (2006) 189-197
14. FDA, March 2008. FDA Draft Guidance for Industry: Coronary Drug-Eluting Stents-Nonclinical and Clinical Studies.
15. García-García H.M., Vaina S., Tsuchida K., and Serruys P.W. Meta-iodobenzylguanidine, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents neointimal hyperplasia. Arch. Cardiol. Mex. 76 (2006) 297-319
16. Gunatillake P., Mayadunne R., and Adhikari R. Recent developments in biodegradable synthetic polymers. Biotechnol. Annu. Rev. 12 (2006) 301-347
17. Hnojewyj, O., Rivelli, P., Shaffer, T.B., 2008. Drug delivery polyanhydride composition and method. US Patent 20,080,014,170.
18. Jamzad, S., Fassihi, R., 2006. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-a technical note. AAPS Pharm. Sci. Tech. 7, Article 33.
19. Kamberi M., Fu K., Lu J., Chemaly M.G., and Feder D. A sensitive high-throughput HPLC assay for simultaneous determination of everolimus and clobetasol propionate. J. Chromatogr. Sci. 46 (2008) 23-29
20. ® on-site system. Rad. Phys. Chem. 57 (2000) 619-623
21. Kipshidze N.N., Tsapenko M.V., Leon M.B., Stone G.W., and Moses J.W. Update on drug eluting coronary stents. Cardiovasc. Ther. 3 (2005) 953-968
22. Kumar N., Langer R.S., Abraham J., and Domb A.J. Polyanhydrides: an overview. Adv. Drug Deliv. Rev. 54 (2002) 889-910
23. Laroia S.T., and Laroia A.T. Drug-eluting stents. A review of the current literature. Cardiol. Rev. 12 (2004) 37-43
24. Lee D.-H., Kim E.-S., and Chang H.-W. Effect of Tween surfactant components for remediation of toluene-contaminated groundwater. Geosci. J. 9 (2005) 261-267
25. Lindström A., Albertson A.-C., and Karlsson S. Quantitative determination of degradation products an effective means to study early stages of degradation in linear and branched poly(butylene adipate) and poly(butylene succinate). Polym. Degrad. Stab. 83 (1996) 487-493
26. Maeng M., Jensen L.O., Kaltoft A., Hansen H.H., Bøttcher M., Lassen J.F., Thayssen P., Krusell L.R., Rasmussen K., Pedersen L., Sørensen H.T., Johnsen S.P., and Thuesen L. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus. Am. J. Cardiol. 102 (2008) 165-172
27. Makino K., Ohshima H., and Kondo T. Mechanism of hydrolytic degradation of poly(L-lactide) microcapsules: effects of pH, ionic strength and buffer concentration. J. Microencapsul. 3 (1986) 203-212
28. Middleton J.C., and Tipton A.J. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21 (2000) 2335-2346
29. Moore J.W., and Flanner H.H. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Tech. 20 (1996) 64-74
30. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., Midwall J., Simonton C.A., Keim E., Wang P., Kuntz R.E., and Moses J.W. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
31. Nashan B. Review of the proliferation inhibitor everolimus. Exp. Opin. Investig. Drugs 11 (2002) 1845-1857
32. Nokhodchi A., Hassan-Zadeh D., Monajjem-Zadeh F., and Taghi-Zadeh N. Effect of various surfactants and their concentration on controlled release of captopril from polymeric matrices. Acta Pharm. 58 (2008) 151-162
33. Nokhodchi A., Norouzi-Sania S., Siahi-Shadbada M.R., Lotfipoora F., and Saeedib M. The effect of various surfactants on the release rate of propranolol hydrochloride from hydroxypropylmethylcellulose (HPMC)-Eudragit matrices. Eur. J. Pharm. Biopharm. 54 (2002) 349-356
34. Oh J.E., Nam Y.S., Lee K.H., and Park T.G. Conjugation of drug to poly(d,l-lactic-co-glycolic acid) for controlled release from biodegradable microspheres. J. Control. Release 57 (1999) 269-280
35. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol. Dial. Transplant. 21 Suppl. 3:iii (2006) 18-23
36. Patel J.K., and Kobashigawa J.A. Everolimus: an immunosuppressive agent in transplantation. Exp. Opin. Pharmacother. 7 (2006) 1347-1355
37. Pendyala L., Jabara R., Shinke T., Chronos N., Robinson K., Li J., and Hou D. Drug-eluting stents: present and future. Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 105-115
38. Ramcharitar S., and Serruys P.W. Fully biodegradable coronary stents: progress to date. Am. J. Cardiovasc. Drugs 8 (2008) 305-314
39. Rastogi A., and Stavchansky S. Drug-eluting stents and beyond. Curr. Pharm. Des. 14 (2008) 2111-2120
40. Regnier F.E. High-performance liquid-chromatography of proteins. Methods Enzymol. 91 (1983) 137-190
41. Roiron C., Sanchez P., Bouzamondo A., Lechat P., and Montalescot G. Drug eluting stents: an updated meta-analysis of randomized controlled trials. Heart 92 (2006) 641-649
42. Serruys P.W., Ong A.T.L., Piek J.J., Neumann F.-J., van der Giessen W.J., Wiemer M., Zeiher A., Grube E., Haase J., Thuesen L., Hamm C., and Otto-Terlouw P.C. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroInterv 1 (2005) 58-65
43. Shameem M., Lee H., and DeLuca P.P. A short-term (accelerated release) approach to evaluate peptide release from PLGA depot-formulations. AAPS Pharm. Sci. 1 (1999) Article 7
44. Sheiban I., Villata G., Bollati M., Sillano D., Lotrionte M., and Biondi-Zoccai G. Next generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc. Health Risk Manage. 4 (2008) 31-38
45. Shi R., Ding T., Liu Q., Han Y., Zhang L., Chen D., and Tian W. In vitro degradation and swelling behaviour of rubbery thermoplastic starch in simulated body and simulated saliva fluid and effects of the degradation products on cells. Polymer Degrad. Stabil. 91 (2006) 3289-3300
46. Tesfamariam B. Drug release kinetics from stent device-based delivery systems. Toxicol. Lett. 30 (2007) 93-102
47. Tesfamariam B. Drug delivery kinetics from stent devise-based delivery systems. J. Cardiovasc. Pharm. 51 (2008) 118-125
48. Varshney, S.K., Hnojewyj, O., Zhang, J., Rivelli, P., 2007. Polyanhydride polymers and their uses in biomedical devices. US Patent 20,070,225,472.
49. Versaci F., Gaspardone A., Tomai F., Ribichini F., Russo P., Proietti I., Ghini A.S., Ferraro V., Chiariello L., Gioffre P.A., Romeo F., and Crea F. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J. Am. Coll. Cardiol. 40 (2002) 1935-1942
50. Vetrovec G.W., Rizik D., Williard C., Snead D., Piotrovski V., and Kopia G. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc. Interv. 67 (2006) 32-37
51. Wiemer W., Seth A., Chandra P., Neuzner J., Richardt G., Piek J.J., Desaga M., Macaya C., Bol C.J., Miquel-Hebert K., De Roeck K., and Serruys P.W. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. Am. Heart J. 156 (2008) 751-757
52. Wise D.L. Encyclopedic Handbook of Biomaterials and Bioengineering (1995), Marcel Dekker, New York
53. Zackrisson G., Ostling G., Skanderberg B., and Anfält T. Accelerated dissolution rate analysis (ACDRA) for controlled release drugs. Application to Roxiam. J. Pharm. Biomed. Anal. 13 (1995) 377-383